Pre-made Eldelumab benchmark antibody ( Whole mAb, anti-CXCL10 therapeutic antibody, Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-¦Ã-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn’s disease and ulcerative colitis.
| Products Name (INN Index) | Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody |
|---|---|
| INN Name | Eldelumab |
| Target | CXCL10 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Bristol-Myers Squibb,Medarex |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Crohn's disease,Ulcerative colitis,Multiple sclerosis,Rheumatoid arthritis,Spinal cord injuries |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | CXCL10 |
| Package |
